Australia Markets closed

Kraig Biocraft Laboratories, Inc. (KBLB)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.0347-0.0003 (-0.71%)
At close: 01:50PM EDT
Full screen
Loading interactive chart…
  • GlobeNewswire

    Kraig Biocraft Laboratories Adds Two New Positions on Research Team to Accelerate Implementation of its Spider Silk Technology Roadmap

    ANN ARBOR, Mich., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces today that it has created and seeks to fill two new senior-level genetic engineering positions within its U.S. based research and development team. These new roles will expand and strengthen the research team’s capabilities in order to accelerate the pace of development

  • GlobeNewswire

    Kraig Biocraft Laboratories Delivers the First Two Hybrid Dragon Silk™ Silkworm Strains for Commercial Production

    ANN ARBOR, Mich., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), the biotechnology company focused on the development and commercialization of spider silk, announces that it has delivered the first two hybrid-cross Dragon Silk™ strains to its third-party production partner in Vietnam. These strains were developed to address the most significant immediate hurdle to large-scale production, the robustness of our silkworms within the la

  • GlobeNewswire

    Kraig Biocraft Laboratories Completes Closeout of $8 Million Financing, Extinguishing All Convertible Debentures with Yorkville Advisors

    ANN ARBOR, Mich., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), the biotechnology company focused on the development and commercialization of spider silk, announces that it has completed the debt-to-equity conversion on $8 million of convertible debentures with Yorkville Advisors. This closeout comes several months ahead of schedule and positions the Company to enter 2023 without any convertible debt obligations to Yorkville Adviso